1. Home
  2. CIVB vs ALT Comparison

CIVB vs ALT Comparison

Compare CIVB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CIVB
  • ALT
  • Stock Information
  • Founded
  • CIVB 1884
  • ALT 1997
  • Country
  • CIVB United States
  • ALT United States
  • Employees
  • CIVB N/A
  • ALT N/A
  • Industry
  • CIVB Major Banks
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CIVB Finance
  • ALT Health Care
  • Exchange
  • CIVB Nasdaq
  • ALT Nasdaq
  • Market Cap
  • CIVB 422.4M
  • ALT 348.6M
  • IPO Year
  • CIVB N/A
  • ALT N/A
  • Fundamental
  • Price
  • CIVB $21.89
  • ALT $4.17
  • Analyst Decision
  • CIVB Buy
  • ALT Strong Buy
  • Analyst Count
  • CIVB 5
  • ALT 7
  • Target Price
  • CIVB $25.40
  • ALT $16.33
  • AVG Volume (30 Days)
  • CIVB 78.6K
  • ALT 2.9M
  • Earning Date
  • CIVB 10-23-2025
  • ALT 11-06-2025
  • Dividend Yield
  • CIVB 3.10%
  • ALT N/A
  • EPS Growth
  • CIVB 33.31
  • ALT N/A
  • EPS
  • CIVB 2.66
  • ALT N/A
  • Revenue
  • CIVB $163,095,000.00
  • ALT $20,000.00
  • Revenue This Year
  • CIVB $18.06
  • ALT N/A
  • Revenue Next Year
  • CIVB $10.83
  • ALT N/A
  • P/E Ratio
  • CIVB $8.23
  • ALT N/A
  • Revenue Growth
  • CIVB 11.28
  • ALT N/A
  • 52 Week Low
  • CIVB $17.47
  • ALT $2.90
  • 52 Week High
  • CIVB $25.59
  • ALT $10.88
  • Technical
  • Relative Strength Index (RSI)
  • CIVB 58.77
  • ALT 55.89
  • Support Level
  • CIVB $21.19
  • ALT $3.73
  • Resistance Level
  • CIVB $22.19
  • ALT $4.35
  • Average True Range (ATR)
  • CIVB 0.41
  • ALT 0.22
  • MACD
  • CIVB 0.00
  • ALT 0.02
  • Stochastic Oscillator
  • CIVB 73.00
  • ALT 69.84

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: